Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.70 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.70 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.70 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.70 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.70 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | GJB2 | P29033 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | CDC25B | P30305 | 6/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31491488 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL15338590 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL1957129 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3752668 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13204994 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13591468 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12896361 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL5961352 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3752664 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6872203 | 1.00 | SSTR1 (0.70) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120118141-A | Nucleoside analogues and uses thereof | 广州市恒诺康医药科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119930717-A | 1-Triazole ribose derivative and preparation method and application thereof | 上海泓博智源医药股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | disclosed |
| EP-3917922-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen BioPharma, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020157694-A9 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen Biopharma, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2020157694-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen Biopharma, Inc. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3497111-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| WO-2018031818-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1913011-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1828215-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006112872-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| EP-0832091-B1 | C-4' MODIFIED ADENOSINE KINASE INHIBITORS | GENSIA SICOR INC (US) | 2004-01-14 | — | — | EP | disclosed |
| US-5763596-A | PYROLO PYRIMIDINE AND PYRAZOLO PYRIMIDINE COMPOUMDS; TREATMENT OF CARDIOVASCULAR AND BRAIN DISORDERS, ANTIINFLAMMATORY AGENTS | METABASIS THERAPEUTICS, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5674998-A | FOR TREATING CARDIOVASCULAR OR BRAIN DISORDERS, OR AS ANTIINFLAMMATORY AGENT | GENSIA INC. (US) | 1997-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | PNP, NUDT1, ADAR | SSTR1 4474/4885SSTR2 4717/4885SSTR4 3806/4885 |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | SSTR1 4244/4885SSTR2 4546/4885SSTR4 3751/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | SSTR1 1404/4885SSTR2 1919/4885SSTR4 1543/4885 |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | NT5C3B, DERA, DUT | SSTR1 1890/4885SSTR2 2106/4885SSTR4 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.